Golden Green, Inc. Cassava Sciences Inc Transaction History

Golden Green, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 14, 2022	BUY	$16.33 - $51.06 $88,916 - $278,021	5,445 New	5,445 $228,000
Q2 2022 Jul 12, 2022	SELL	$17.22 - $38.47 $254,959 - $569,586	-14,806 Closed	0 $0
Q1 2022 Apr 18, 2022	SELL	$32.6 - $53.05 $51,540 - $83,872	-1,581 Reduced 9.65%	14,806 $550,000
Q4 2021 Jan 21, 2022	SELL	$36.77 - $90.91 $629,502 - $1.56 Million	-17,120 Reduced 51.09%	16,387 $716,000
Q3 2021 Oct 08, 2021	BUY	$41.79 - $135.3 $1.07 Million - $3.48 Million	25,721 Added 330.35%	33,507 $2.08 Million
Q2 2021 Jul 14, 2021	BUY	$32.15 - $89.72 $88,894 - $248,075	2,765 Added 55.07%	7,786 $665,000
Q1 2021 Apr 13, 2021	SELL	$7.09 - $87.95 $76,983 - $954,961	-10,858 Reduced 68.38%	5,021 $226,000
Q4 2020 Jan 25, 2021	BUY	$6.79 - $12.25 $107,818 - $194,517	15,879 New	15,879 $108,000

187

16.3M

3.49M

8.08M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $66.2M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Golden Green, Inc., based on Form 13F filings with the SEC.

Stay updated on Golden Green, Inc. with notifications on news.